BioMarin Pharmaceutical Inc BMRN Cash Flow

Biomarin pharmaceutical inc (BMRN)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)
81,381	15,024	55,036	-37,435	-56,473	-3,650	-12,620	-16,792	-44,149	-51,392	-12,527	-36,833	-16,290	-90,720	-37,425	-419,014	-83,051	68,617	-90,926	-81,989	-67,501	-69,797	7,445	-33,502	-38,115	-61,990	-53,020	-21,533	-39,810	-53,012	-5,357	-32,006	-23,972	-26,735	-17,653	-5,077	-4,371	-12,189	217,334	-477	1,151
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
25,964	25,790	30,739	26,344	22,427	24,716	26,345	20,977	23,633	28,664	20,700	19,085	19,412	20,107	29,422	28,657	18,726	12,886	12,038	11,446	10,817	5,966	14,225	13,676	12,004	-1,514	13,312	12,868	11,348	10,897	11,667	11,173	10,598	8,580	9,350	8,531	8,585	7,931	7,819	6,577	5,410
Non-cash interest expense
4,618	4,565	525	4,461	4,409	5,087	8,799	8,699	8,601	8,508	8,191	7,846	7,755	7,654	7,514	7,425	7,337	7,250	7,163	7,080	7,000	6,920	6,840	6,767	6,698	5,523	63	73	216	-	-	-	-	-	-	-	-	-	-	-	-
(Accretion of discount) Amortization of premium on investments
-60	103	387	619	891	411	-810	802	-761	-915	-835	-667	-660	-619	-145	-227	-309	-561	-675	-524	-417	-1,463	-2,007	-1,841	-1,900	-1,750	-1,320	-1,373	-1,456	-1,394	-1,337	-886	-852	-981	-1,002	-973	-1,080	-947	-1,005	-1,303	-1,198
Stock-based compensation
46,994	38,102	39,173	39,829	42,761	36,558	37,047	38,606	36,608	33,585	35,903	40,101	30,674	37,421	33,145	33,898	30,177	30,566	28,758	29,509	22,692	31,159	20,463	17,521	17,267	21,738	16,790	14,340	11,508	11,926	11,990	12,269	11,155	11,188	11,784	10,786	10,151	9,835	10,294	9,627	8,606
Gain on sale of nonfinancial assets
59,495	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of equity investment
-	-	-	-	-	-	-	-	-	0	0	0	3,252	1,912	7	-2,027	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on termination of leases
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,199	-372	407	8,858	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Impairment of assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	3	6,704	0	0	0	0	-	-	-	-
Equity in the loss of BioMarin/Genzyme LLC
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-338	-	-147	-163	-401	-253	-336	102	-734	-609	-608	-667	-542	-	-	-2,246	691
Net gain from sale of investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-25	0	0	927
Deferred income taxes
10,603	-22,980	-49,697	-9,379	-704	-35,643	-3,054	-15,693	-13,988	80,614	-13,380	-12,329	-10,441	-9,354	-27,569	-169,763	-21,368	-91,456	29,580	-7,151	-7,800	-13,244	-7,651	-4,543	-179	10,307	-9,490	-9,679	-43	689	-10,753	-569	712	-2,481	-149	3,083	3,910	-7,512	-223,065	0	0
Excess tax benefit from stock option exercises
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78	-142	527	-	-126	53	278	398	-118	325	128	377	12	66	18	306	81	-387	415	509	19	13	0
Unrealized foreign exchange (gain) loss
-9,400	-241	15	-1,218	419	5,769	6,304	11,309	-5,616	-1,910	-9,218	3,140	1,730	3,520	3,079	1,356	6,526	3,084	6,288	4,517	5,686	3,186	252	-1,283	-1,323	-1,034	295	1,033	364	1,683	2,506	462	1,878	-1,475	-3,582	-2,518	401	551	2,194	1,415	60
Non-cash changes in the fair value of contingent consideration
-4	-441	755	-7,369	12,260	-3,540	11,008	-3,803	5,631	6,960	-3,813	5,842	1,353	-207	2,112	-62,002	2,936	-43,558	495	14,324	282	365	1,831	1,220	8,151	381	8,832	-3,767	4,751	12,113	617	-9,123	5,181	-4,185	-2,234	4,131	493	607	-3,143	-799	-654
Debt conversion expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	813	1,732	0	10,420	-	0	0	0	-	-	-	-	-	-	-	-
Other
383	1,661	-3,585	3,584	19	1,888	2,231	-1,110	-662	-1,278	-851	-2,837	-969	708	-339	-179	-526	-1,404	-338	-851	130	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable, net
31,898	-23,951	30,773	-20,660	51,690	-41,610	18,468	51,159	26,257	3,658	4,764	2,783	14,051	-540	1,773	34,206	16,044	16,513	-37,733	10,798	26,789	22,469	-902	11,790	-7,406	-6,939	9,682	-5,282	11,279	-8,224	16,540	-5,078	989	-2,025	451	408	19,622	7,842	1,052	-4,924	9,066
Inventory
20,706	54,983	19,452	34,854	-1,735	13,515	25,725	-4,650	-10,843	16,005	20,516	37,709	22,660	4,710	18,202	31,315	10,285	3,520	18,546	9,579	19,344	-18,775	10,704	16,540	13,870	1,113	6,388	6,474	7,127	7,870	700	-3,939	-6,054	14,490	3,329	2,232	369	17,957	7,963	4,017	1,099
Other current assets
-8,302	13,749	8,270	15,101	-10,112	22,043	-6,313	4,961	-2,924	-100	17,077	6,473	-2,763	-20,872	4,742	-787	-2,399	-53,770	30,181	-5,733	3,522	-7,572	12,923	-4,067	927	10,297	-4,583	-2,045	8,404	-4,648	-6,022	3,063	11,113	-8,690	2,889	1,207	2,051	-2,593	641	1,638	-2,925
Other assets
441	1,783	2,519	6,813	-2,220	-2,213	-3,300	5,349	1,099	1,409	-79	582	527	-23	3,563	207	1,232	1,766	1,888	-167	-330	-192	2,069	3,719	920	-4,259	-78	-631	1,016	-2,829	670	195	6,040	947	1,639	-150	-1,599	3,178	-498	1,775	871
Accounts payable and accrued liabilities
-94,733	55,342	59,318	4,499	-42,070	50,479	20,899	18,898	-51,887	47,249	34,554	41,536	-77,822	24,647	9,708	3,184	-90,744	89,374	34,557	23,603	-57,236	7,110	37,004	12,946	-19,020	8,942	19,057	-963	-6,732	21,586	14,393	-2,394	3,826	8,312	4,146	-483	-2,204	-2,152	2,565	8,164	-6,411
Other long-term liabilities
5,144	742	-7,893	8,805	1,474	5,170	1,081	3,071	-408	2,295	38	715	2,744	-962	3,607	-3,444	-4,614	-43	-6,280	-2,116	9,186	3,209	1,067	-1,770	587	4,191	3,351	-757	2,774	-2,591	4,390	2,850	1,385	943	450	9	560	860	693	-702	1,049
Net cash used in operating activities
-15,194	57,343	70,125	-24,338	-54,868	49,374	47,200	-33,857	-42,509	14,614	38,292	18,780	-80,443	-210	-10,368	-45,805	-171,454	-65,847	-2,850	-12,991	-137,811	-23,907	-8,557	-11,465	-26,493	-8,997	-9,492	-6,817	-32,029	11,986	14,214	-1,420	-7,171	-513	8,861	13,566	-3,499	-15,782	9,057	22,221	3,250
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment
40,554	50,785	32,854	32,631	28,756	42,079	49,859	22,518	30,164	39,890	42,482	47,757	69,090	51,574	26,096	25,506	45,204	103,809	44,556	35,456	43,832	27,767	25,170	40,518	23,607	29,753	13,202	10,412	11,826	13,895	15,013	9,484	6,179	8,680	56,388	1,910	6,241	10,741	9,372	15,240	14,108
Maturities and sales of investments
94,701	104,533	212,201	203,583	219,894	136,671	545,094	207,507	104,462	100,282	91,061	84,701	149,916	64,768	19,021	102,513	181,267	162,927	107,586	30,063	124,137	600,837	87,810	50,275	69,391	56,018	77,526	72,568	82,531	72,378	58,412	33,010	74,037	54,897	81,455	61,626	84,013	70,622	85,057	28,627	22,055
Purchases of available-for-sale securities
40,104	103,526	142,177	146,477	239,843	195,555	93,740	199,525	145,933	45,653	478,808	76,598	54,388	329,356	311,479	0	58,914	30,311	113,610	440,832	288,431	58,098	316,018	48,614	84,306	215,850	61,011	49,411	68,770	105,351	64,346	175,909	36,562	131	82,733	58,355	74,210	72,773	59,414	26,516	62,956
Proceeds from sale of nonfinancial assets
67,159	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of promissory note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	3,326	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of intangible assets
3,463	10,057	2,553	4,064	1,706	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Business acquisitions, net of cash acquired
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	538,392	-	-	-	-	0	0	0	9,875	-	0	0	0	-	-	-	-	0	18,826	0	14,124
Investments in BioMarin/Genzyme LLC
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	485	0	0	1,258	0	655	655	593	718	1,450	0	1,465
Other
335	-939	939	740	68	0	-831	742	99	193	0	169	1,391	548	0	0	150	-	-	-	1,027	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by (used in) investing activities
77,404	-48,896	48,678	19,671	-50,479	-70,963	402,326	4,722	-71,734	139,546	-430,229	-39,823	25,047	-309,649	-326,937	75,540	76,999	79,551	-63,080	-445,198	-750,871	462,684	-187,478	-40,357	-38,522	-306,485	3,313	12,260	-7,940	-52,353	-20,947	-152,383	30,038	-34,914	-58,321	706	2,969	-13,610	-4,005	-13,129	-70,598
Proceeds from exercises of awards under equity incentive plans
10,116	9,843	2,755	13,215	5,798	11,845	10,717	31,792	13,134	14,740	5,460	27,573	13,086	24,729	26,484	19,493	3,521	11,530	6,088	17,401	28,026	42,269	9,533	8,390	19,712	12,350	14,447	21,202	24,580	45,394	10,381	13,607	13,679	10,156	11,858	8,445	3,133	13,215	6,722	3,983	9,183
Taxes paid related to net share settlement of equity awards
28,844	1,729	4,051	6,795	30,105	1,739	5,566	5,715	22,899	1,644	5,239	8,689	17,935	4,228	2,417	12,036	40,788	1,021	2,402	18,831	735	522	552	6,221	473	256	154	5,762	225	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from public offering of common stock, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	888,257	0	0	0	117,464	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Repayments of convertible debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	813	1,732	0	10,420	-	0	0	0	-	-	-	-	-	-	-	-
Payment of contingent consideration
-	-	-	-	-	-	-	-	-	0	0	0	1,894	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Excess tax benefit from stock option exercises
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78	-142	527	-	-126	53	278	398	-118	325	128	377	12	66	18	306	81	-387	415	509	19	13	0
Principal repayments of financing leases
-943	-3,062	-678	-673	-674	0	0	0	0	-	-	-	-	-588	0	-3	3	-528	1	-779	-1,284	-20	16	-690	-17	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment on maturity of 2013 convertible note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	98	-	0	0	0	-	-	-	-	-	-	-	-
Repayment of capital lease obligations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	143	-	142	143	250	355	53	156	315	77	33	42	43
Net cash used in financing activities
-19,671	4,042	-1,975	-51,760	-24,981	-366,362	5,151	-17,031	-9,765	13,096	481,936	18,856	-6,743	19,913	737,005	7,454	-37,264	9,518	3,765	-2,351	914,791	41,522	8,871	-3,159	136,964	704,928	12,299	15,622	13,822	39,564	10,306	248,974	13,447	10,445	7,758	7,902	3,233	-10,068	6,708	-2,276	9,140
Effect of exchange rate changes on cash
-3,353	1,737	-1,185	-365	715	-251	96	-403	-40	-627	-13,464	8,817	2,043	-9,073	1,680	-1,673	5,132	-2,528	-2,153	634	-1,025	-2,818	452	-80	-952	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
39,186	14,226	115,643	-56,792	-129,613	-388,202	454,773	-46,569	-124,048	166,629	76,535	6,630	-60,096	-299,019	401,380	35,516	-126,587	20,694	-64,318	-459,906	25,084	477,481	-186,712	-55,061	70,997	387,216	6,120	21,065	-26,147	-803	3,573	95,171	36,314	-24,982	-41,702	22,174	2,703	-39,460	11,760	6,816	-58,208
SUPPLEMENTAL CASH FLOW DISCLOSURES:
Cash paid for income taxes
2,267	3,638	2,155	3,027	906	885	933	3,127	11,731	2,151	5,403	9,965	6,376	694	1,194	20,754	73,215	707	1,563	12,456	1,358	12,608	9,287	12,710	381	1,732	1,777	10,742	646	991	677	3,175	1,739	1,009	1,088	1,682	616	677	1,721	929	254
Cash paid for interest
1,403	2,775	1,482	2,812	1,483	4,102	1,690	4,303	1,528	4,257	-232	4,519	0	-	-	-	-	-	-	-	-	4,565	-96	4,854	1	-1,079	205	1,035	1,998	3,068	230	3,074	293	3,196	336	3,046	637	3,402	2,151	2,702	1,822
Stock-based compensation capitalized into inventory
-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,209	3,282	2,469	2,869	2,779	3,012	2,480	2,503	1,754	1,856	2,053	1,902	1,829	1,397	993	1,305	1,181	967	894	1,320	1,499	1,306	1,173	1,434	1,381	1,244	1,080
Depreciation capitalized into inventory
-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,409	4,858	4,135	3,622	3,689	3,736	3,580	2,963	2,641	2,424	2,924	2,795	2,830	2,784	2,607	2,591	2,469	1,213	1,062	-	-	-	-	1,909	1,500	213	1,466
SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:
Decrease in accounts payable and accrued liabilities related to fixed assets
-19,927	13,390	-2,334	35	-3,502	6,472	56	3,633	-11,367	-739	4,253	-3,003	-26,297	34,146	3,142	-2,342	-14,788	6,735	-4,475	14,074	-20,985	19,528	3,216	3,193	-9,171	12,492	-366	-718	-6,407	-1,999	318	-1,979	3,149	-2,053	477	5,135	-3,239	12,563	-13,396	1,313	4,477
Conversion of convertible debt, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	155	824	0	8,133	-	-	-	-	13,503	31,512	27	238,277	105	0	0	0	-	-	-	-	-	-	-	-
Accrual for inventory purchases related to the acquisition of the Merck PKU Business
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-1,114	2,436	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred offering costs reclassified into additional paid-in-capital as a result of conversion of convertible debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	303	0	2,315	-	0	0	0	-	-	-	-	-	-	-	-
Release of escrow balance for purchase of San Rafael Corporate Center
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	116,500	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Equipment acquired through capital leases
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	366	1,313	0	0	0
Change in asset retirement obligation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Changes in contingent acquisition consideration payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21,100